ALLISON COTHERN: Open Payments
NPI 1013539832 · DALLAS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,495 in 71 payments from 24 companies in 2025. Trend: 2023 $1,376 · 2024 $944 · 2025 $1,495
Food & beverage: $1,495
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 11 | $215 |
| AstraZeneca Pharmaceuticals LP | 8 | $192 |
| PFIZER INC. | 5 | $109 |
| GlaxoSmithKline, LLC. | 5 | $86 |
| Corcept Therapeutics | 2 | $79 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 4 | $79 |
| Astellas Pharma US Inc | 5 | $78 |
| Otsuka America Pharmaceutical, Inc. | 3 | $77 |
| SANOFI-AVENTIS U.S. LLC | 3 | $70 |
| Dexcom, Inc. | 3 | $69 |
Products named: FARXIGA, Ozempic, JARDIANCE, Wegovy, Korlym, Veozah, REXULTI, TZIELD.
Industry payments across TX — which companies pay providers there.
